Cite
Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas.
MLA
Piccaluga, Pier Paolo, et al. “Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas.” Leukemia & Lymphoma, vol. 45, no. 9, Sept. 2004, pp. 1791–95. EBSCOhost, https://doi.org/10.1080/1042819042000219485.
APA
Piccaluga, P. P., Martinelli, G., Rondoni, M., Malagola, M., Gaitani, S., Isidori, A., Bonini, A., Gugliotta, L., Luppi, M., Morselli, M., Sparaventi, G., Visani, G., & Baccarani, M. (2004). Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas. Leukemia & Lymphoma, 45(9), 1791–1795. https://doi.org/10.1080/1042819042000219485
Chicago
Piccaluga, Pier Paolo, Giovanni Martinelli, Michela Rondoni, Michele Malagola, Stavroula Gaitani, Alessandro Isidori, Alessandro Bonini, et al. 2004. “Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas.” Leukemia & Lymphoma 45 (9): 1791–95. doi:10.1080/1042819042000219485.